TRPM2-AS Promotes Bladder Cancer by Targeting miR-22-3p and Regulating GINS2 mRNA Expression.
GINS2
TRPM2-AS
bladder cancer
miR-22-3p
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
09
2020
accepted:
19
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Bladder cancer (BLCA) refers to the malignancy growth that spreads from the bladder linings to the bladder muscles. However, the impact of miR-22-3p and lncRNA TRPM2-AS on this tumor has generated divergent views in the literature. This research aimed to study the effects of lncRNA TRPM2-AS on BLCA and its interaction with miR-22-3p and GINS2 mRNA. qRT-PCR was employed to measure the expression of TRPM2-AS, miR-22-3p and GINS2 mRNA in bladder tissues and cells. The subcellular localization of TRPM2-AS in T24 and 5637 cell lines was identified using a cell fractionation system. Luciferase assay, RIP assay and RNA pull-down assay were later performed to validate the direct binding relationship between TRPM2-AS, miR-22-3p and GINS2 mRNA. Several experiments were conducted to determine the viability, proliferation, colony formation and apoptosis of the cell lines. Findings indicated that TRPM2-AS was significantly upregulated in BLCA tissues and cell lines. Apart from that, it was observed that TRPM2-AS knockdown significantly inhibited the viability, proliferation and colony formation of BCLA cells, but it promoted the apoptosis of the BCLA cells. A significant downstream target of TRPM2-AS, miR-22-3p was found to show a lower expression level in BLCA tissues and cell lines. However, the inhibition of miR-22-3p considerably enhanced BLCA cell phenotypes. As well as discovering that GINS2 mRNA was a downstream target of miR-22-3p and was significantly upregulated in BLCA, experimental results also indicated that the knockdown of GINS2 suppressed BLCA cell phenotypes. This research confirmed that TRPM2-AS could promote BCLA by binding to miR-22-3p to increase GINS2 expression. This novel interactome in BLCA cell lines might provide more insights into BLCA therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer (BLCA) refers to the malignancy growth that spreads from the bladder linings to the bladder muscles. However, the impact of miR-22-3p and lncRNA TRPM2-AS on this tumor has generated divergent views in the literature. This research aimed to study the effects of lncRNA TRPM2-AS on BLCA and its interaction with miR-22-3p and GINS2 mRNA.
METHODS
METHODS
qRT-PCR was employed to measure the expression of TRPM2-AS, miR-22-3p and GINS2 mRNA in bladder tissues and cells. The subcellular localization of TRPM2-AS in T24 and 5637 cell lines was identified using a cell fractionation system. Luciferase assay, RIP assay and RNA pull-down assay were later performed to validate the direct binding relationship between TRPM2-AS, miR-22-3p and GINS2 mRNA. Several experiments were conducted to determine the viability, proliferation, colony formation and apoptosis of the cell lines.
RESULTS
RESULTS
Findings indicated that TRPM2-AS was significantly upregulated in BLCA tissues and cell lines. Apart from that, it was observed that TRPM2-AS knockdown significantly inhibited the viability, proliferation and colony formation of BCLA cells, but it promoted the apoptosis of the BCLA cells. A significant downstream target of TRPM2-AS, miR-22-3p was found to show a lower expression level in BLCA tissues and cell lines. However, the inhibition of miR-22-3p considerably enhanced BLCA cell phenotypes. As well as discovering that GINS2 mRNA was a downstream target of miR-22-3p and was significantly upregulated in BLCA, experimental results also indicated that the knockdown of GINS2 suppressed BLCA cell phenotypes.
CONCLUSION
CONCLUSIONS
This research confirmed that TRPM2-AS could promote BCLA by binding to miR-22-3p to increase GINS2 expression. This novel interactome in BLCA cell lines might provide more insights into BLCA therapy.
Identifiants
pubmed: 33658791
doi: 10.2147/OTT.S282151
pii: 282151
pmc: PMC7914110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1219-1237Informations de copyright
© 2021 Tian et al.
Déclaration de conflit d'intérêts
There is no conflict of interest existed among the authors.
Références
Neoplasma. 2020 May;67(3):484-491
pubmed: 32064882
Subcell Biochem. 2012;62:135-56
pubmed: 22918584
Sci Rep. 2016 Apr 22;6:24922
pubmed: 27102850
Cancer Biol Ther. 2019;20(6):760-773
pubmed: 30810442
Int J Biochem Cell Biol. 2020 Mar;120:105683
pubmed: 31887411
Neoplasia. 2010 Nov;12(11):877-88
pubmed: 21082043
Biomed Pharmacother. 2018 Nov;107:382-389
pubmed: 30099342
Biomed Pharmacother. 2016 Dec;84:1568-1574
pubmed: 27829549
Breast Cancer Res Treat. 2014 Nov;148(2):423-36
pubmed: 25348432
Cell Res. 2008 Nov;18(11):1128-40
pubmed: 18957938
Int J Med Sci. 2013 Oct 30;10(12):1795-804
pubmed: 24273454
J Cell Biochem. 2019 Oct;120(10):17650-17661
pubmed: 31190355
Mol Cells. 2016 May 31;39(5):375-81
pubmed: 27117456
Biochem J. 2010 Jan 15;425(3):489-500
pubmed: 20070258
Cell Death Dis. 2018 Mar 7;9(3):372
pubmed: 29515098
J Cell Biochem. 2019 Oct;120(10):16921-16933
pubmed: 31104318
J Cell Physiol. 2019 Jul;234(7):11256-11264
pubmed: 30565694
Biomed Pharmacother. 2017 Dec;96:1103-1108
pubmed: 29239821
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Ir J Med Sci. 2018 Aug;187(3):621-628
pubmed: 29081064
Cancer Gene Ther. 2019 Mar;26(3-4):103-113
pubmed: 30177819
Oncogene. 2015 Apr 16;34(16):2094-102
pubmed: 24931166
Trends Cell Biol. 2007 Jun;17(6):271-8
pubmed: 17467990
Am J Transl Res. 2016 Nov 15;8(11):4932-4941
pubmed: 27904693
Cell. 2014 Jul 31;158(3):593-606
pubmed: 25083870
J Cell Physiol. 2020 Nov;235(11):7747-7756
pubmed: 31681988
Andrologia. 2020 Apr;52(3):e13539
pubmed: 32030798
Cancer Lett. 2013 Oct 10;339(2):159-66
pubmed: 23791884
Mol Endocrinol. 1988 Jan;2(1):73-7
pubmed: 2840568
Gastric Cancer. 2020 Mar;23(2):228-240
pubmed: 31451992
Oncol Lett. 2018 Aug;16(2):2591-2598
pubmed: 30013653
Cancer Lett. 2013 Oct 1;339(1):8-14
pubmed: 23856029
Eur Urol. 2017 Jan;71(1):109-110
pubmed: 27417034
Cell Death Dis. 2018 Feb 12;9(2):209
pubmed: 29434190
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
EMBO Rep. 2001 Nov;2(11):986-91
pubmed: 11713189
Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2626-2634
pubmed: 28678322
Clin Cancer Res. 2018 Jan 15;24(2):445-459
pubmed: 29084921
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1057-1066
pubmed: 30931636
Oncol Rep. 2017 May;37(5):2652-2662
pubmed: 28405687
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Tumour Biol. 2017 Feb;39(2):1010428317691191
pubmed: 28231726
Thorac Cancer. 2020 Mar;11(3):549-560
pubmed: 31923353
Cell Oncol (Dordr). 2019 Aug;42(4):571-578
pubmed: 30887286